Vol. 40 | No. 2 | July-December 2012Back

Open Access

Primary Malignant Pericardial Mesothelioma in a 55 Year Old Female Presenting as Massive Pericardial Effusion: A Case Report

Abe F. Montejo, Yvonne Bettina E. Montejo
Dec 2012 DOI 10.69944/pjc.84dae00c30

More Info

Abe F. Montejo, MD, Yvonne Bettina E. Montejo, MD  

Chong Hua Hospital, Cebu City 

 

References
  1. Kralstein J, Frishman WH. Malignant pericardial diseases: diagnosis  and treatment. Cardiol Clin 1987;5:583–589. 
  2. Reynen K. Frequency of primary tumors of the heart. Am J Cardiol.  1996;77(1):107. 
  3. Lam KY, Dickens P, Chan AC . Tumors of the heart. A 20-year  experience with a review of 12,485 consecutive autopsies. Arch Pathol  Lab Med. 1993;117(10):1027.  
  4. Hillerdal G: Malignant mesothelioma 1982: review of 4,710  published cases. Br J Dis Chest 1983;77:321–143. 
  5. Thomason, R. et al Primary Malignant Mesothelioma of the  Pericardium Case Report and Literature Review. Texas Heart Institute  Journal 1994;21. 
  6. Teta MJ, Mink PJ, Lau E, et al. US mesothelioma patterns 1973- 2002: indicators of change and insights into background rates. Eur  J Cancer Prev 2008; 17:525. 
  7. Gossinger HD, Siostrznek P, Zangeneh M, et al. Magnetic resonance  imaging findings in a patient with pericardial mesothelioma. Am  Heart J 1988;115:1321–2. 
  8. Gemba K, Fujimoto N, Kato K, Aoe K, Takeshima Y, Inai K,  Kishimoto T. National survey of malignant mesothelioma and  asbestos exposure in Japan. Cancer Sci. 2011 Nov 29. 1349-7006. 
  9. Travis, WD, Brambilla, E, Muller-Hermelink, HK, Harris, CC.  Pathology and Genetics: Tumors of the Lung, Pleura, Thymus, and  Heart, IARC, 2004. 
  10. Fazekas T, Tiszlavicz L, Ungi I. [Primary malignant pericardial  mesothelioma]. Orv Hetil 1991;132:2677–80. 
  11. Szczechowski L, Janiec K. [Pericardial mesothelioma as a very rare  cause of recurrent cerebral emboli. Wiad Lek 1992;45:857–61.
  12. Cherian G, Habashy A, Uthaman B, Cherian J, Salama A, Anim J. Detectio and follow-up of mediastinal lymph node enlargement in  tuberculous pericardial effusions using computed tomography. Am  J Med 2003;114:319-22. 
  13. Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Mesothelioma and radical  multimodality therapy: who benefits? Chest 1995; 107:345S.
  14. Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic  diagnosis of malignant mesothelioma: a consensus statement from the  International Mesothelioma Interest Group. Arch Pathol Lab Med  2009; 133:1317. 
  15. Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of  pemetrexed plus carboplatin in malignant pleural mesothelioma. J  Clin Onco 2006;24:1443-8. 
  16. Kindler HL, Herndon JE, Zhang C, Green MR. Irinotecan for  malignant mesothelioma A phase II trial by the Cancer and Leukemia  Group B. Lung Cancer 2005;48:423-8.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.